CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25 enrolled
Drug / intervention
Ketamine 50 MG/ML +1 moredrug
Likely dose
Ketamine 50 MG/MLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04227704
NCT04227704Phase 3Completed
CompareCT.gov

Postpartum Depression After Cesarean Delivery: Ketamine as a Preventative Intervention: A Feasibility Pilot-study

Washington University School of Medicine·interventional·Posted Jan 14, 2020·Updated Jan 26, 2023

In Brief

A Phase 3 clinical trial evaluating Ketamine 50 MG/ML and Control for Postpartum Depression. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The investigators plan to randomise participants to receive ketamine or placebo control subcutaneously or by 40-minute intravenous infusions and will follow them up for 42 days to assess the incidence of postpartum depression. This feasibility pilot study is designed to explore the adequacy of the study procedures and tolerability of the interventions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostpartum Depression
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 14, 2020
Enrollment StartNov 12, 2020
Primary CompletionAug 9, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.5 years ago

Interventions

Ketamine 50 MG/MLdrug

Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).

Controldrug

Administration of 0.9% Sodium Chloride (N/S)